Introdução: O câncer gástrico é o 5º câncer mais incidente, excetuando-se tumores de pele não melanoma e a 3ª causa de morte decorrente de câncer no mundo. Os locais mais comuns de metástases do câncer gástrico são: fígado (48%), peritônio (32%), pulmão (15%) e osso (12%). Objetivo: apresentar o curso de metástase cutânea em decorrência de um adenocarcinoma gástrico. Metodologia: Estudo descritivo do tipo relato de caso, cujos dados foram obtidos no prontuário físico da paciente. Apresentação do caso: Reportamos o caso de uma paciente do sexo feminino, 44 anos, submetida a tratamento cirúrgico e quimioterápico devido a um adenocarcinoma gástrico. Um ano e quatro meses após a intervenção inicial, observou-se o aparecimento de lesões cutâneas hipercrômicas, dolorosas, difusas e não pruriginosas, localizadas principalmente em tórax, dorso e membros superiores. A biópsia cutânea confirmou a hipótese de metástase cutânea de adenocarcinoma gástrico. Conclusão: No contexto do tratamento do câncer gástrico, faz-se importante a vigilância de novos sinais e sintomas, como lesões cutâneas insidiosas, aventando a possibilidade de tumor cutâneo metastático.
Introduction: In advanced breast cancer, local treatment is considered palliative. However, although there are some polemic opinions about the surgical treatment, some of the latest studies have emphasized that in advanced cases primary tumor resection (PTR) is related to better outcomes. This review aims to evaluate how resection of the original tumor impacts women with metastatic breast cancer, considering the most recent studies about this subject. Methods: The search was performed in MEDLINE, Scopus, PMC, Current Contents and Wiley Online Library databases; 23 articles - from 2016 to 2019 - were selected and 11 were included in this review. As inclusion criteria were considered: studies presenting outcomes about resection of the primary tumor, comparison between chemotherapy/ hormone therapy/ targeted cancer therapies and surgical intervention, studies published from 2016 to 2019 and available in English, Spanish or Portuguese. We excluded those which did not approach PTR, did not present outcomes of interest (progression-free survival comparison between PTR and systemic therapy) or only discussed systemic therapy, as well as those published before 2016. Results: It was reported in 6 studies that progression-free survival is better on those who underwent surgery. PTR was also related to longer median overall survival in women submitted to surgery, up to 16 months higher when compared to the ones who were not. Enhanced survival even pertained to surgical groups regardless of tumor size. Conclusion: Based in the analysis, PTR in metastatic breast cancer can be related to higher overall survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.